Free tool
FAERS Monitor: Adreview
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022290 or its brand name (Adreview, Iobenguane Sulfate I-123). Reports on generic versions are filed under their own applications.
Reports
114
Serious
64
56% of reports
Hospitalization
13
Death reported
6
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- no adverse event41
- neutropenia22
- drug ineffective21
- radioisotope scan abnormal20
- mucosal inflammation14
- fatigue5
- febrile neutropenia5
- neuroblastoma recurrent5
- product use issue4
- pyrexia4
- therapy partial responder4
- vomiting4
- false positive investigation result3
- myelodysplastic syndrome3
- therapy non-responder3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 6 |
| 2016 | 10 |
| 2017 | 14 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 9 |
| 2021 | 5 |
| 2022 | 21 |
| 2023 | 11 |
| 2024 | 12 |
| 2025 | 4 |
| 2026 | 7 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,045 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| radioisotope scan abnormalSignal | 20 | 5376.6 | 3586.3 | 99,295 |
| neuroblastoma recurrentSignal | 5 | 4663.8 | 1957.1 | 18,414 |
| false positive investigation resultSignal | 3 | 550.2 | 179.8 | 1,138 |
| mucosal inflammationSignal | 14 | 98.7 | 60.4 | 1,259 |
| therapy partial responderSignal | 4 | 47.3 | 18.1 | 138 |
| no adverse eventSignal | 41 | 41.8 | 32.7 | 1,604 |
| myelodysplastic syndromeSignal | 3 | 38.3 | 12.5 | 75 |
| neutropeniaSignal | 22 | 29.9 | 20.5 | 589 |
| febrile neutropeniaSignal | 5 | 13.9 | 5.9 | 48 |
| therapy non-responderSignal | 3 | 12.3 | 4.0 | 21 |
| product use issueSignal | 4 | 3.9 | 1.5 | 6 |
| drug ineffectiveSignal | 21 | 2.9 | 2.0 | 27 |
| pyrexia | 4 | 2.1 | 0.8 | 1 |
| vomiting | 4 | 1.6 | 0.6 | 0 |
| fatigue | 5 | 1.2 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.